Annual Revenue
$13.12 B
+$944.30 M+7.76%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual revenue is currently $13.12 billion, with the most recent change of +$944.30 million (+7.76%) on 31 December 2023. During the last 3 years, it has risen by +$4.62 billion (+54.37%). REGN annual revenue is now -18.38% below its all-time high of $16.07 billion, reached on 31 December 2021.REGN Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$3.72 B
+$173.60 M+4.89%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly revenue is currently $3.72 billion, with the most recent change of +$173.60 million (+4.89%) on 30 September 2024. Over the past year, it has increased by +$358.00 million (+10.65%). REGN quarterly revenue is now -27.59% below its all-time high of $5.14 billion, reached on 30 June 2021.REGN Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$13.85 B
+$358.00 M+2.65%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM revenue is currently $13.85 billion, with the most recent change of +$358.00 million (+2.65%) on 30 September 2024. Over the past year, it has increased by +$749.80 million (+5.72%). REGN TTM revenue is now -16.12% below its all-time high of $16.51 billion, reached on 31 March 2022.REGN TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.8% | +10.7% | +5.7% |
| 3 y3 years | +54.4% | +7.8% | +2.3% |
| 5 y5 years | +154.9% | +113.4% | +173.8% |
REGN Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -18.4% | +54.4% | -24.9% | +30.2% | -16.1% | +13.8% |
| 5 y | 5 years | -18.4% | +154.9% | -27.6% | +113.4% | -16.1% | +173.8% |
| alltime | all time | -18.4% | >+9999.0% | -27.6% | >+9999.0% | -16.1% | >+9999.0% |
Regeneron Pharmaceuticals Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.72 B(+4.9%) | $13.85 B(+2.7%) |
| June 2024 | - | $3.55 B(+12.8%) | $13.49 B(+3.0%) |
| Mar 2024 | - | $3.15 B(-8.4%) | $13.10 B(-0.1%) |
| Dec 2023 | $13.12 B(+7.8%) | $3.43 B(+2.1%) | $13.12 B(+0.2%) |
| Sept 2023 | - | $3.36 B(+6.5%) | $13.10 B(+3.4%) |
| June 2023 | - | $3.16 B(-0.1%) | $12.67 B(+2.4%) |
| Mar 2023 | - | $3.16 B(-7.4%) | $12.37 B(+1.6%) |
| Dec 2022 | $12.17 B(-24.3%) | $3.41 B(+16.3%) | $12.17 B(-11.2%) |
| Sept 2022 | - | $2.94 B(+2.8%) | $13.71 B(-3.6%) |
| June 2022 | - | $2.86 B(-3.6%) | $14.23 B(-13.8%) |
| Mar 2022 | - | $2.97 B(-40.1%) | $16.51 B(+2.7%) |
| Dec 2021 | $16.07 B(+89.1%) | $4.95 B(+43.4%) | $16.07 B(+18.7%) |
| Sept 2021 | - | $3.45 B(-32.8%) | $13.54 B(+9.4%) |
| June 2021 | - | $5.14 B(+103.2%) | $12.38 B(+34.6%) |
| Mar 2021 | - | $2.53 B(+4.4%) | $9.20 B(+8.2%) |
| Dec 2020 | $8.50 B(+29.6%) | $2.42 B(+5.6%) | $8.50 B(+7.0%) |
| Sept 2020 | - | $2.29 B(+17.5%) | $7.94 B(+7.4%) |
| June 2020 | - | $1.95 B(+6.8%) | $7.39 B(+5.3%) |
| Mar 2020 | - | $1.83 B(-1.9%) | $7.01 B(+6.9%) |
| Dec 2019 | $6.56 B(+27.4%) | $1.86 B(+6.9%) | $6.56 B(+29.7%) |
| Sept 2019 | - | $1.74 B(+10.5%) | $5.06 B(+1.6%) |
| June 2019 | - | $1.58 B(+14.9%) | $4.98 B(-0.6%) |
| Mar 2019 | - | $1.37 B(+278.5%) | $5.01 B(-2.7%) |
| Dec 2018 | $5.15 B(-12.4%) | $362.60 M(-78.2%) | $5.15 B(-19.2%) |
| Sept 2018 | - | $1.66 B(+3.5%) | $6.37 B(+2.6%) |
| June 2018 | - | $1.61 B(+6.4%) | $6.20 B(+2.3%) |
| Mar 2018 | - | $1.51 B(-4.5%) | $6.06 B(+3.3%) |
| Dec 2017 | $5.87 B(+20.8%) | $1.58 B(+5.4%) | $5.87 B(+6.4%) |
| Sept 2017 | - | $1.50 B(+2.1%) | $5.52 B(+5.4%) |
| June 2017 | - | $1.47 B(+11.5%) | $5.24 B(+5.2%) |
| Mar 2017 | - | $1.32 B(+7.5%) | $4.98 B(+2.4%) |
| Dec 2016 | $4.86 B(+18.4%) | $1.23 B(+0.5%) | $4.86 B(+2.7%) |
| Sept 2016 | - | $1.22 B(+0.6%) | $4.73 B(+1.8%) |
| June 2016 | - | $1.21 B(+1.0%) | $4.65 B(+4.8%) |
| Mar 2016 | - | $1.20 B(+9.4%) | $4.43 B(+8.1%) |
| Dec 2015 | $4.10 B(+45.5%) | $1.10 B(-3.5%) | $4.10 B(+7.8%) |
| Sept 2015 | - | $1.14 B(+13.9%) | $3.81 B(+12.1%) |
| June 2015 | - | $998.62 M(+14.8%) | $3.40 B(+10.9%) |
| Mar 2015 | - | $869.61 M(+8.4%) | $3.06 B(+8.6%) |
| Dec 2014 | $2.82 B(+34.0%) | $802.33 M(+10.5%) | $2.82 B(+7.3%) |
| Sept 2014 | - | $725.79 M(+9.0%) | $2.63 B(+5.2%) |
| June 2014 | - | $665.70 M(+6.4%) | $2.50 B(+9.1%) |
| Mar 2014 | - | $625.74 M(+2.5%) | $2.29 B(+8.8%) |
| Dec 2013 | $2.10 B(+52.7%) | $610.41 M(+2.2%) | $2.10 B(+10.3%) |
| Sept 2013 | - | $597.03 M(+30.5%) | $1.91 B(+9.7%) |
| June 2013 | - | $457.64 M(+4.1%) | $1.74 B(+9.7%) |
| Mar 2013 | - | $439.66 M(+6.0%) | $1.59 B(+15.1%) |
| Dec 2012 | $1.38 B(+209.2%) | $414.60 M(-3.1%) | $1.38 B(+26.8%) |
| Sept 2012 | - | $427.69 M(+40.5%) | $1.09 B(+42.6%) |
| June 2012 | - | $304.40 M(+31.3%) | $762.00 M(+34.8%) |
| Mar 2012 | - | $231.79 M(+88.5%) | $565.41 M(+26.8%) |
| Dec 2011 | $445.82 M(-2.9%) | $122.98 M(+19.6%) | $445.82 M(-2.3%) |
| Sept 2011 | - | $102.83 M(-4.6%) | $456.52 M(-0.7%) |
| June 2011 | - | $107.81 M(-3.9%) | $459.67 M(-1.7%) |
| Mar 2011 | - | $112.20 M(-16.1%) | $467.74 M(+1.9%) |
| Dec 2010 | $459.07 M(+21.0%) | $133.68 M(+26.1%) | $459.07 M(+8.7%) |
| Sept 2010 | - | $105.98 M(-8.5%) | $422.20 M(-2.6%) |
| June 2010 | - | $115.89 M(+11.9%) | $433.68 M(+6.3%) |
| Mar 2010 | - | $103.53 M(+7.0%) | $407.82 M(+7.5%) |
| Dec 2009 | $379.27 M(+59.1%) | $96.80 M(-17.6%) | $379.27 M(+12.1%) |
| Sept 2009 | - | $117.45 M(+30.5%) | $338.31 M(+18.1%) |
| June 2009 | - | $90.03 M(+20.1%) | $286.43 M(+11.4%) |
| Mar 2009 | - | $74.98 M(+34.3%) | $257.06 M(+7.8%) |
| Dec 2008 | $238.46 M(+90.7%) | $55.84 M(-14.9%) | $238.46 M(-3.6%) |
| Sept 2008 | - | $65.58 M(+8.1%) | $247.35 M(+21.2%) |
| June 2008 | - | $60.65 M(+7.6%) | $204.08 M(+23.2%) |
| Mar 2008 | - | $56.38 M(-12.9%) | $165.62 M(+32.5%) |
| Dec 2007 | $125.02 M | $64.73 M(+190.1%) | $125.02 M(+77.0%) |
| Sept 2007 | - | $22.31 M(+0.5%) | $70.64 M(+10.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2007 | - | $22.20 M(+40.6%) | $63.95 M(+4.8%) |
| Mar 2007 | - | $15.79 M(+52.6%) | $61.02 M(-3.8%) |
| Dec 2006 | $63.45 M(-4.1%) | $10.35 M(-33.8%) | $63.45 M(-10.0%) |
| Sept 2006 | - | $15.62 M(-18.9%) | $70.53 M(-0.8%) |
| June 2006 | - | $19.26 M(+5.7%) | $71.09 M(+4.2%) |
| Mar 2006 | - | $18.22 M(+4.6%) | $68.20 M(+3.0%) |
| Dec 2005 | $66.19 M(-62.0%) | $17.42 M(+7.6%) | $66.19 M(-30.9%) |
| Sept 2005 | - | $16.19 M(-1.1%) | $95.86 M(-17.5%) |
| June 2005 | - | $16.37 M(+1.0%) | $116.18 M(-9.4%) |
| Mar 2005 | - | $16.21 M(-65.6%) | $128.24 M(-26.3%) |
| Dec 2004 | $174.02 M(+202.7%) | $47.09 M(+28.9%) | $174.02 M(+17.4%) |
| Sept 2004 | - | $36.52 M(+28.5%) | $148.20 M(+14.8%) |
| June 2004 | - | $28.42 M(-54.2%) | $129.07 M(+17.8%) |
| Mar 2004 | - | $61.99 M(+191.4%) | $109.56 M(+89.9%) |
| Dec 2003 | $57.50 M(+161.5%) | $21.27 M(+22.3%) | $57.71 M(+39.6%) |
| Sept 2003 | - | $17.39 M(+95.2%) | $41.35 M(+35.5%) |
| June 2003 | - | $8.91 M(-12.1%) | $30.52 M(+12.3%) |
| Mar 2003 | - | $10.14 M(+106.4%) | $27.18 M(+23.6%) |
| Dec 2002 | $21.99 M(+0.1%) | $4.91 M(-25.2%) | $21.99 M(+2.4%) |
| Sept 2002 | - | $6.57 M(+17.9%) | $21.48 M(+5.3%) |
| June 2002 | - | $5.57 M(+12.7%) | $20.39 M(-1.0%) |
| Mar 2002 | - | $4.94 M(+12.3%) | $20.60 M(-6.2%) |
| Dec 2001 | $21.97 M(-62.9%) | $4.40 M(-19.7%) | $21.97 M(-40.1%) |
| Sept 2001 | - | $5.48 M(-5.2%) | $36.71 M(-20.6%) |
| June 2001 | - | $5.78 M(-8.5%) | $46.23 M(-15.9%) |
| Mar 2001 | - | $6.31 M(-67.0%) | $55.00 M(-7.1%) |
| Dec 2000 | $59.28 M(+71.8%) | $19.14 M(+27.6%) | $59.18 M(+13.9%) |
| Sept 2000 | - | $15.00 M(+3.1%) | $51.95 M(+7.7%) |
| June 2000 | - | $14.55 M(+38.6%) | $48.25 M(+21.8%) |
| Mar 2000 | - | $10.50 M(-11.8%) | $39.60 M(+14.8%) |
| Dec 1999 | $34.50 M(-9.9%) | $11.90 M(+5.3%) | $34.50 M(+14.2%) |
| Sept 1999 | - | $11.30 M(+91.5%) | $30.20 M(+1.7%) |
| June 1999 | - | $5.90 M(+9.3%) | $29.70 M(-20.4%) |
| Mar 1999 | - | $5.40 M(-28.9%) | $37.30 M(-2.9%) |
| Dec 1998 | $38.30 M(+42.4%) | $7.60 M(-29.6%) | $38.40 M(+6.7%) |
| Sept 1998 | - | $10.80 M(-20.0%) | $36.00 M(+5.6%) |
| June 1998 | - | $13.50 M(+107.7%) | $34.10 M(+25.4%) |
| Mar 1998 | - | $6.50 M(+25.0%) | $27.20 M(+1.1%) |
| Dec 1997 | $26.90 M(+11.6%) | $5.20 M(-41.6%) | $26.90 M(-4.6%) |
| Sept 1997 | - | $8.90 M(+34.8%) | $28.20 M(+10.6%) |
| June 1997 | - | $6.60 M(+6.5%) | $25.50 M(+1.6%) |
| Mar 1997 | - | $6.20 M(-4.6%) | $25.10 M(+4.1%) |
| Dec 1996 | $24.10 M(-12.0%) | $6.50 M(+4.8%) | $24.10 M(+3.0%) |
| Sept 1996 | - | $6.20 M(0.0%) | $23.40 M(0.0%) |
| June 1996 | - | $6.20 M(+19.2%) | $23.40 M(-5.6%) |
| Mar 1996 | - | $5.20 M(-10.3%) | $24.80 M(-6.4%) |
| Dec 1995 | $27.40 M(+18.1%) | $5.80 M(-6.5%) | $26.50 M(-6.7%) |
| Sept 1995 | - | $6.20 M(-18.4%) | $28.40 M(-8.7%) |
| June 1995 | - | $7.60 M(+10.1%) | $31.10 M(+14.8%) |
| Mar 1995 | - | $6.90 M(-10.4%) | $27.10 M(+16.8%) |
| Dec 1994 | $23.20 M(+118.9%) | $7.70 M(-13.5%) | $23.20 M(+26.1%) |
| Sept 1994 | - | $8.90 M(+147.2%) | $18.40 M(+40.5%) |
| June 1994 | - | $3.60 M(+20.0%) | $13.10 M(+21.3%) |
| Mar 1994 | - | $3.00 M(+3.4%) | $10.80 M(+9.1%) |
| Dec 1993 | $10.60 M(-7.8%) | $2.90 M(-19.4%) | $9.90 M(+6.5%) |
| Sept 1993 | - | $3.60 M(+176.9%) | $9.30 M(+14.8%) |
| June 1993 | - | $1.30 M(-38.1%) | $8.10 M(-19.0%) |
| Mar 1993 | - | $2.10 M(-8.7%) | $10.00 M(-12.3%) |
| Dec 1992 | $11.50 M(+57.5%) | $2.30 M(-4.2%) | $11.40 M(+2.7%) |
| Sept 1992 | - | $2.40 M(-25.0%) | $11.10 M(+4.7%) |
| June 1992 | - | $3.20 M(-8.6%) | $10.60 M(+16.5%) |
| Mar 1992 | - | $3.50 M(+75.0%) | $9.10 M(+19.7%) |
| Dec 1991 | $7.30 M(+46.0%) | $2.00 M(+5.3%) | $7.60 M(+10.1%) |
| Sept 1991 | - | $1.90 M(+11.8%) | $6.90 M(+9.5%) |
| June 1991 | - | $1.70 M(-15.0%) | $6.30 M(+8.6%) |
| Mar 1991 | - | $2.00 M(+53.8%) | $5.80 M(+16.0%) |
| Dec 1990 | $5.00 M | $1.30 M(0.0%) | $5.00 M(+35.1%) |
| Sept 1990 | - | $1.30 M(+8.3%) | $3.70 M(+54.2%) |
| June 1990 | - | $1.20 M(0.0%) | $2.40 M(+100.0%) |
| Mar 1990 | - | $1.20 M | $1.20 M |
FAQ
- What is Regeneron Pharmaceuticals annual revenue?
- What is the all time high annual revenue for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual revenue year-on-year change?
- What is Regeneron Pharmaceuticals quarterly revenue?
- What is the all time high quarterly revenue for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly revenue year-on-year change?
- What is Regeneron Pharmaceuticals TTM revenue?
- What is the all time high TTM revenue for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM revenue year-on-year change?
What is Regeneron Pharmaceuticals annual revenue?
The current annual revenue of REGN is $13.12 B
What is the all time high annual revenue for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual revenue is $16.07 B
What is Regeneron Pharmaceuticals annual revenue year-on-year change?
Over the past year, REGN annual revenue has changed by +$944.30 M (+7.76%)
What is Regeneron Pharmaceuticals quarterly revenue?
The current quarterly revenue of REGN is $3.72 B
What is the all time high quarterly revenue for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly revenue is $5.14 B
What is Regeneron Pharmaceuticals quarterly revenue year-on-year change?
Over the past year, REGN quarterly revenue has changed by +$358.00 M (+10.65%)
What is Regeneron Pharmaceuticals TTM revenue?
The current TTM revenue of REGN is $13.85 B
What is the all time high TTM revenue for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM revenue is $16.51 B
What is Regeneron Pharmaceuticals TTM revenue year-on-year change?
Over the past year, REGN TTM revenue has changed by +$749.80 M (+5.72%)